01 November 2017 1 Min Read
Aspen completes acquisition of AstraZeneca’s anaesthetics portfolio
Aspen Pharmacare’s share price was up in mid-morning trade, following the announcement of the conclusion of the commercialisation rights agreement
Subscribe to our website to read this article and support quality journalism.
If you’ve already subscribed, simply sign in.
Subscribe Sign In